Future studies are needed to evaluate the therapeutic utility of strategies that promote the effects of CYP-derived EETs in NAFLD/NASH, and improve our understanding of the mechanisms underlying the contribution of sEH and EETs to the regulation of NAFLD/NASH-associated chronic hepatic inflammation. This evidence concerns the gene EPHX2 and metabolic dysfunction-associated steatotic liver disease.